Financial Performance Highlights (₹ in Lakhs)

Quarterly Comparison

| Particulars | Q1 2026-27 | Q4 2025-26 | Q1 2025-26 | FY 2025-26 |

| Revenue from Operations | 15,399 | 23,402 | 13,522 | 68,142 |

| EBITDA* | 1,588 | 4,066 | 1,429 | 7,825 |

| Finance Costs | 328 | 317 | 254 | 1,047 |

| Forex Gain/Loss | 198 | -763 | 239 | -1,595 |

| Depreciation | 577 | 452 | 426 | 1,747 |

| Tax Expenses | 210 | 648 | 244 | 863 |

| Net Profit | 670 | 1,887 | 745 | 2,573 |

| EBITDA Margin | 10.31% | 17.38% | 10.57% | 11.48% |

*EBITDA excluding other income and forex losses

Historical Financial Snapshot (₹ in Lakhs)

| Particulars | Q1 2026-27 | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |

| Equity Share Capital | 4,829 | 4,829 | 4,829 | 4,821 | 4,821 | 4,821 | 4,325 | 4,325 |

| Other Equity | 48,881 | 48,199 | 47,006 | 44,303 | 39,104 | 37,796 | 20,178 | 14,643 |

| Net Worth | 53,709 | 53,028 | 51,835 | 49,125 | 43,925 | 42,617 | 24,503 | 18,968 |

| Fixed Assets (net) | 37,780 | 37,124 | 32,160 | 27,830 | 23,457 | 18,623 | 15,508 | 14,139 |

| Borrowings | 16,687 | 15,269 | 14,779 | 9,923 | 7,524 | 7,248 | 6,429 | 7,806 |

| Sales/Other Income | 15,605 | 68,177 | 63,359 | 62,920 | 55,405 | 48,813 | 50,980 | 36,013 |

| EBITDA | 1,588 | 7,790 | 7,290 | 7,441 | 5,180 | 8,739 | 8,178 | 4,696 |

| Finance Costs | 328 | 1,047 | 934 | 859 | 608 | 512 | 624 | 891 |

| Depreciation | 577 | 1,747 | 1,559 | 1,289 | 1,271 | 1,110 | 1,019 | 958 |

| Tax Expenses | 210 | 863 | 1,340 | 1,659 | 376 | 2,075 | 2,173 | 726 |

| Net Profit/(loss) | 670 | 2,573 | 3,855 | 5,096 | 2,723 | 6,103 | 6,161 | 2,120 |

| Earning per share (Rs.) | 1.39 | 5.33 | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 | 4.86 |

Business Overview

Kopran Limited is an integrated pharmaceutical company operating in two major verticals:

API Business (operated through wholly owned subsidiary Kopran Research Laboratories Ltd.)

  • Development, manufacturing and sale of diverse APIs and Advanced Intermediates
  • One of the leaders in Atenolol and a major player in Sterile Carbapenems
  • Facilities located at MIDC Mahad, Maharashtra (11,900 sq. mts. built-up area)
  • Product segments include: Anti-hypertensive, Macrolide, Neuromodulator, Urological, Anti-infective/Anti-acne, Sterile Carbapenem, Sterile Cephalosporin, Anti-thrombotic, Intermediate, Anti-Diabetic, Cardiology, NSAIDs, Anti Lipid

Formulations Business

  • Development and manufacturing of oral solid dosages and dry powder formulations
  • 100% export-oriented to both Regulated and Non-Regulated markets
  • Manufacturers of more than 100 dosages including Tablets, Capsules, Dry Powder
  • Facilities located at Khopoli, Maharashtra (11,432 sq. mts. built-up area)
  • Dedicated facilities for Penicillin-based and Non-Penicillin-based finished oral dosage forms

Formulations Accreditations

Approved by 15 countries including MHRA (UK), SAPHRA South Africa, MMA Malta (EU GMP), Health Canada, FDA Philippines, DAV Vietnam, FDA Thailand, TMDA Tanzania, NDA Uganda, PPB Kenya, EFDA Ethiopia, MCAZ Zimbabwe, MOH Oman, MOH Iraq, MOH Yemen

API Accreditations

Not specifically detailed in the document.

Strategic Imperatives

  • Focus on R&D to develop niche, high-value/high-volume APIs and intermediates
  • Capacity expansion
  • Compliance with Global Regulatory standards
  • Synergies between APIs and formulations
  • API and R&D facility at Panoli (Gujarat)
  • Cost leadership through development of intermediates, reducing China dependence, operational optimization
  • Process improvements and automation of packing lines in formulations
  • Prudent capital allocation and increasing asset to turnover ratio
  • Business development through leveraging customer base, new geographies, and regulatory filings

Board of Directors

  • Mr. Surendra Somani - Chairman & Managing Director
  • Mr. Varun Surendra Somani - Director
  • Mrs. Namrata Somani - Director
  • Mr. Narayan Atal - Independent Director